Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 7/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28166201 | 0.82 | CA2 (0.31) | HCRTR2HCRTR1TMEM97SIGMAR1CA2 | |
| SCHEMBL28304852 | 0.81 | CA2 (0.33) | CA2 | |
| SCHEMBL15795509 | 0.76 | HCRTR1 (0.31) | HCRTR2HCRTR1TMEM97SIGMAR1 | |
| SCHEMBL1030224 | 0.72 | HCRTR2 (0.39) | HCRTR2HCRTR1TMEM97SIGMAR1CA2 | |
| SCHEMBL2038232 | 0.72 | HCRTR2 (0.39) | HCRTR2HCRTR1TMEM97SIGMAR1CA2 | |
| Bicarbonate SCHEMBL7042448 | 0.72 | HCRTR2 (0.36) | HCRTR2HCRTR1TMEM97SIGMAR1CA2 | |
| SCHEMBL1030223 | 0.72 | HCRTR2 (0.39) | HCRTR2HCRTR1TMEM97SIGMAR1CA2 | |
| SCHEMBL5310871 | 0.72 | HCRTR2 (0.33) | HCRTR2HCRTR1TMEM97SIGMAR1CA2 | |
| SCHEMBL16280834 | 0.72 | HCRTR2 (0.33) | HCRTR2HCRTR1TMEM97SIGMAR1CA2 | |
| SCHEMBL18302598 | 0.72 | CA2 (0.33) | HCRTR2HCRTR1TMEM97SIGMAR1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108948045-A | A kind of preparation method of tesirolimus | 鲁南制药集团股份有限公司 | 2018-12-07 | — | — | CN | claimed |
| US-8754207-B2 | Process for the preparation of rapamycin derivatives | CADILA HEALTHCARE LIMITED (IN) | 2014-06-17 | — | — | US | disclosed |
| US-20120202988-A1 | PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202988-A1 | PROCESS FOR THE PREPARATION OF RAPAMYCIN DERIVATIVES | RICTOR, MTOR, RPTOR | HCRTR2 2893/4885HCRTR1 2908/4885TMEM97 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.